Regenxbio Inc (RGNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Regenxbio Inc (RGNX) has a cash flow conversion efficiency ratio of -3.614x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-76.19 Million) by net assets ($21.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RGNX net asset quality score to measure how much of total assets are equity-financed.
Regenxbio Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Regenxbio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Regenxbio Inc (RGNX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Regenxbio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regenxbio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Yongli Belting Co Ltd
SHE:300230
|
0.037x |
|
Kambi Group PLC
ST:KAMBI
|
0.089x |
|
Shanghai Canature Environmental
SHE:300272
|
0.033x |
|
Kaufman Et Broad
PA:KOF
|
0.043x |
|
Shenzhen Bingchuan Network Co Ltd
SHE:300533
|
0.010x |
|
GREENLIGHT CAP.RE A DL-01
F:G8L
|
0.050x |
|
SSAW Hotels & Resorts Group Co.Ltd.
SHE:301073
|
N/A |
|
Zhejiang Kanglongda Special
SHG:603665
|
0.024x |
Annual Cash Flow Conversion Efficiency for Regenxbio Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Regenxbio Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Regenxbio Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $102.73 Million | $-123.96 Million | -1.207x | -80.97% |
| 2024-12-31 | $259.65 Million | $-173.12 Million | -0.667x | +4.83% |
| 2023-12-31 | $311.74 Million | $-218.41 Million | -0.701x | -74.30% |
| 2022-12-31 | $516.20 Million | $-207.49 Million | -0.402x | -240.36% |
| 2021-12-31 | $764.30 Million | $218.88 Million | 0.286x | +300.10% |
| 2020-12-31 | $377.75 Million | $-54.06 Million | -0.143x | +40.18% |
| 2019-12-31 | $450.20 Million | $-107.70 Million | -0.239x | -216.33% |
| 2018-12-31 | $508.85 Million | $104.65 Million | 0.206x | +164.91% |
| 2017-12-31 | $183.03 Million | $-57.99 Million | -0.317x | -5.54% |
| 2016-12-31 | $161.74 Million | $-48.56 Million | -0.300x | -189.10% |
| 2015-12-31 | $216.81 Million | $-22.52 Million | -0.104x | -124.67% |
| 2014-12-31 | $-5.70 Million | $-2.40 Million | 0.421x | -70.04% |
| 2013-12-31 | $-2.14 Million | $-3.01 Million | 1.406x | -- |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more